Compare ADMA Biologics Inc (ADMA) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Banco Santander SA — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Banco Santander SA trades at $13.59 (market cap $203.67B). The key difference: Banco Santander SA is far larger — about 95.6× ADMA Biologics Inc's market cap, and Banco Santander SA pays a 1.96% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SAN | |
|---|---|---|
Market Cap | $2.13B | $203.67B |
Sector | Health | Financials |
52-Week High | $20.38 | $14.37 |
52-Week Low | $7.60 | $8.31 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Banco Santander (SAN) trades at $14.19, up 1.72% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.72% net income margin and 16.18% ROE, though recent quarters saw EPS misses. Recent developments include the completion of the TSB acquisition and AI-driven efficiency initiatives, positioning the company for growth amid positive analyst sentiment.
The outlook for SAN is cautiously optimistic, with upside driven by cost-saving measures and strategic acquisitions. Risks include regulatory scrutiny in Spain and volatile cash flows. Analysts maintain a 64% buy rating, highlighting value potential, but investors should monitor execution on profitability targets and macroeconomic impacts on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
